← back to search

Kerry L. Reynolds

Massachusetts Mental Health Center · US
Area of research
Oncology · Cardiology and Cardiovascular Medicine
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies, CAR-T cell therapy research, and COVID-19 and healthcare impacts.
h-index
54
citations
14,267
works
334
NIH funding
primary concept
Medicine
email

Recent publications

Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer.
2026cited by 1position: contributordoi
Inhibition of the PD-1 immune checkpoint and the development of heart failure in the presence of prior cardiac ischemia.
2026cited by 0position: contributordoi
Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors.
2026cited by 0position: contributordoi
Data from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
2026cited by 0position: contributordoi
Supplementary Table 4 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
2026cited by 0position: contributordoi
Supplementary Table 3 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
2026cited by 0position: contributordoi
Supplementary Table 2 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
2026cited by 0position: contributordoi
Table 2 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
2026cited by 0position: contributordoi
Supplementary Table 1 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
2026cited by 0position: contributordoi
Supplementary Figure 1 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
2026cited by 0position: contributordoi
Table 3 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
2026cited by 0position: contributordoi
Table 1 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
2026cited by 0position: contributordoi
Figure 1 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
2026cited by 0position: contributordoi
Figure 2 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
2026cited by 0position: contributordoi
Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy
JAMA Network Open 2025cited by 38position: lastdoi
Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors
Journal for ImmunoTherapy of Cancer 2025cited by 14position: middledoi
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors.
2025cited by 4position: contributordoi
Predictors of Long-Term Survival in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis.
2025cited by 3position: contributordoi
Beyond the Point: Learning From Outcomes After Inpatient Immune Checkpoint Inhibitor Therapy.
2025cited by 0position: contributordoi
It Takes a Village! Navigating the Challenges and Opportunities in Immune-Related Adverse Event Management.
2025cited by 0position: contributordoi
Immune responses in checkpoint myocarditis across heart, blood and tumour
Nature 2024cited by 53position: middledoi
Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis
Nature Medicine 2024cited by 52position: middledoi
Cardiovascular Considerations Before Cancer Therapy
JACC CardioOncology 2024cited by 46position: middledoi
Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study
BMJ 2024cited by 34position: middledoi
Identification of Immune Checkpoint Inhibitor–Induced Diabetes
JAMA Oncology 2024cited by 27position: middledoi
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy.
2024cited by 21position: contributordoi
Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease Codes in Patient Records.
2024cited by 20position: contributordoi
F18-FDG PET imaging as a diagnostic tool for immune checkpoint inhibitor–associated acute kidney injury
Journal of Clinical Investigation 2024cited by 15position: middledoi
Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis.
2023cited by 26position: contributordoi
A Rare Presentation of Aggressive Renal Cell Carcinoma and the Utility of Early Molecular Testing in Rapidly Progressing Malignancies: A Case Report.
2023cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 32 papers (2020–2026)Leyre Zubiri · Massachusetts Institute of Technology18 papers (2020–2026)David P. Ryan · University of New England12 papers (2026–2026)Motaz Qadan · Harvard University12 papers (2026–2026)Ryan B. Corcoran · Stanford University12 papers (2026–2026)Nussara Pakvisal · Chulalongkorn University12 papers (2026–2026)Jeffrey W. Clark · Chris O’Brien Lifehouse12 papers (2026–2026)Leontios Pappas · 12 papers (2026–2026)Jill N. Allen · 12 papers (2026–2026)Bruce Giantonio · 12 papers (2026–2026)David T. Ting · Universidade Federal Fluminense12 papers (2026–2026) · 12 papers (2026–2026)Bennett A. Caughey · Duke University Hospital12 papers (2026–2026)Nora K. Horick · Milton District Hospital12 papers (2026–2026)Aparna R. Parikh · Elsevier, Inc.12 papers (2026–2026) · 12 papers (2026–2026)Ben Ouyang · University of Toronto12 papers (2026–2026)Kruti B. Vora · Massachusetts General Hospital12 papers (2026–2026) · 12 papers (2026–2026)Elizabeth P. Walsh · Harvard University12 papers (2026–2026)